.Attributes Medicine, Released online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research study, after a typical follow-up of 11 months, clients along with metastatic stomach growths who received biomarker-matched treatments based on flowing tumor DNA profiling revealed a greater scientific perk than those receiving unequaled therapy.